Agilent Technologies (A) said Thursday that it has received European Union certification for PD-L1 IHC 22C3 pharmDx Code SK006 as a companion diagnostic to help identify patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma who may be treated with Merck's (MRK) Keytruda.

The company said the approval expands PD-L1 testing to support treatment decisions with Keytruda.

The test is also indicated in the EU to help identify patients who may also be eligible for Keytruda treatment for other tumor types, including non-small cell lung cancer, esophageal cancer, cervical cancer, head and neck squamous cell carcinoma, triple-negative breast cancer, gastric or gastroesophageal junction adenocarcinoma, and urothelial carcinoma, Agilent said.

Shares of Agilent were up 1% pre-bell Thursday.